v3.25.2
Revenue (Details)
€ in Thousands
1 Months Ended 6 Months Ended
Feb. 28, 2023
EUR (€)
Feb. 28, 2023
USD ($)
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2022
USD ($)
shares
Oct. 31, 2021
EUR (€)
Oct. 31, 2021
USD ($)
Sep. 30, 2021
EUR (€)
shares
Sep. 30, 2021
USD ($)
shares
Jun. 30, 2025
EUR (€)
Jun. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2024
EUR (€)
Sep. 30, 2021
USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]                          
Deferred income | €                 € 44,435     € 51,371  
Eli Lilly and Company                          
Disclosure of disaggregation of revenue from contracts with customers [line items]                          
Deferred income             € 2,047   € 44,374     € 50,930 $ 2,429,000
Issue of ordinary shares (in shares) | shares     9,381,586 9,381,586     3,989,976 3,989,976          
Proceeds from issuing shares     € 14,122 $ 15,000,000     € 25,270 $ 30,000,000          
Discount on shares issued     € 451 $ 480,000                  
Additional consideration to be received if counterparty exercises option to expand partnership | $                     $ 50,000,000    
Number of performance obligations in collaboration agreement                 1 1      
Milestone payments received         € 16,849 $ 20,000,000              
Value of milestones reached during the period                 € 1,781 $ 2,000,000      
Eli Lilly and Company | Milestone payments                          
Disclosure of disaggregation of revenue from contracts with customers [line items]                          
Milestone payments received € 56,412 $ 60,000,000